Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

What are the side effects of lamzede?

See the DrugPatentWatch profile for lamzede

Common Side Effects of Lamzede

Lamzede (otesecon disodium), approved for non-ambulatory children with late-onset Pompe disease, most often causes infusion-related reactions. These affect about 91% of patients and include fever, cough, vomiting, respiratory distress, hives, rash, itching, and low blood pressure. Most occur during or within 2 hours of infusion and are mild to moderate, resolving with slowing or pausing the infusion and supportive care like antihistamines or steroids.[1][2]

Serious Side Effects and Risks

Anaphylaxis happens in around 3% of patients, with symptoms like throat swelling, trouble breathing, rapid heartbeat, nausea, and dizziness—stop infusion immediately and seek emergency treatment. Other risks include severe hypersensitivity reactions and loss of effectiveness over time (anti-drug antibodies in 89% of patients, potentially worsening respiratory function). Monitor for infections at the IV site.[1][2]

How Side Effects Are Managed During Infusion

Start at a low dose (1 mg/kg every 2 weeks), ramping up over 8 weeks to 20 mg/kg every 2 weeks. Premedicate with antihistamines, antipyretics, and corticosteroids if reactions occur. Slow infusion rate for milder issues; discontinue for anaphylaxis. Long-term, test for antibodies every 3 months.[1][2]

Differences from Other Pompe Treatments

Compared to alglucosidase alfa (Lumizyme/Myozyme), Lamzede has fewer severe anaphylaxis cases (3% vs. higher rates) but similar infusion reactions. Its every-2-week dosing contrasts with weekly infusions for the older drug, potentially reducing reaction frequency.[2]

Patient Experiences and Long-Term Concerns

In trials, 100% of 13 patients had reactions, mostly mild, but respiratory decline occurred in some with high antibody titers. No data on adults or ambulatory patients yet. Report symptoms to FDA's MedWatch; pregnancy/breastfeeding safety unknown.[1][2]

[1] Lamzede Prescribing Information, FDA.gov (https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761224s000lbl.pdf)
[2] Lamzede HCP Site, AVROBIO (https://lamzedehcp.com/)



Other Questions About Lamzede :

Is Lamzede used for alpha-mannosidosis? How does lamzede treat alpha mannosidosis? What are the side effects of lamzede? How does lamzede treat mannosidosis?




DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2026. All rights reserved. Privacy